IAA (Insulin Autoantibodies) ELISA Kit kit

Insulin autoantibodies (IAA) are antibodies directed against endogenous or exogenous insulin, often appearing as early immune markers of autoimmune activity against pancreatic β-cells. They are typically among the first autoantibodies to develop in individuals predisposed to type 1 diabetes (T1D), particularly in young children. The presence of IAA reflects a loss of immune tolerance to insulin-producing cells, marking the initiation of the autoimmune process that leads to β-cell destruction and insulin deficiency. As a biomarker, IAA helps identify individuals at risk for T1D before the onset of hyperglycemia.

In research settings, IAA are used to study the immunopathogenesis of type 1 diabetes and to understand the timing and progression of autoimmune responses. They are valuable in longitudinal studies aimed at identifying genetic and environmental factors that trigger β-cell autoimmunity. Researchers also use IAA measurements to evaluate the effectiveness of immunomodulatory therapies designed to delay or prevent T1D onset, as changes in antibody titers can indicate therapeutic impact on immune activity.

Clinically, IAA testing is used in conjunction with other diabetes-associated autoantibodies—such as GAD65, IA-2, and ZnT8 antibodies—to confirm autoimmune diabetes and differentiate type 1 from type 2 or monogenic forms. The detection of IAA in at-risk individuals enables early diagnosis and monitoring of disease progression, while in patients already receiving insulin therapy, their presence can also reflect immune responses to exogenous insulin. Overall, IAA serve as critical biomarkers for both early detection and mechanistic understanding of autoimmune diabetes, supporting advances in prediction, prevention, and personalized treatment strategies.

This product is manufactured in Germany by Medipan GmbH.